Fractyl Health’s Post

Incredible panel today at JPM24 on GLP1 with: Sarah Emond, CEO of Institute for Clinical and Economic Review; Dan Mendelson, CEO of Morgan Health; and Asst Prof Diana Thiara, MD of University of California, San Francisco... Key discussion points: 1) Great data on efficacy of GLP1s means that payors globally cannot ignore this category of drugs. Clearly, this is becoming seminal category of drugs that will have long term health effects on relevant patient populations. Speculation around the size of the addressable market potentially reaching US$100B. 2) Biggest issue will be around affordability of GLP1s for the patient populations that need them. Unless prices come down significantly, health systems will not be able to afford the cost of making GLP1s available to the patients that need them. 3) Warnings of weight rebound and deterimental health effects for patients who are taken off GLP1 after the start of treatment. 4) Plenty of room for innovation to continue to change the market. Next-generation GLP1s, cell therapy, regenerative medicine, and business models(subscription, direct-to-patient sales). Many shifts expected in the next 12 months. Great session with outstanding panelists. I learned alot, and the summary does not do justice to the excellent discussion. #JPM24 #GLP1

Learn more about the clinical values of the EndoClot® Submucosal Injection System (SIS). #OlympusPost

The updated #guidelines encompass 7 overarching principles and 11 recommendations concerning treatment approaches and pharmacological therapies for #PsA. https://brnw.ch/21wJm8i

The road to unlocking the full potential of GLP-1 agonists in treating chronic conditions is paved with obstacles. In our latest whitepaper, OPEN Health experts provide their take on the major challenges key stakeholders face and how to get past them. https://hubs.la/Q02mZll60 #WorldObesityDay #HEOR #MedComms #PatientEngagement #GLP1

The road to unlocking the full potential of GLP-1 agonists in treating chronic conditions is paved with obstacles. In our latest whitepaper, OPEN Health experts provide their take on the major challenges key stakeholders face and how to get past them. #WorldObesityDay #HEOR #MedComms #patient

New #AvalereInsight + White Paper: To assess the potential implications of #Medicare negotiation on the #CardiovascularDisease landscape, the Partnership to Advance Cardiovascular commissioned Avalere to analyze the unique dynamics facing #CVD drug development and how #IRA incentives may affect the timing of core development decisions and timelines. Read our findings here: https://lnkd.in/ePSvhWfQ #InflationReductionAct

The road to unlocking the full potential of GLP-1 agonists in treating chronic conditions is paved with obstacles. In our latest whitepaper, OPEN Health experts provide their take on the major challenges key stakeholders face and how to get past them. https://hubs.la/Q02mZjTF0 #WorldObesityDay #HEOR #MedComms #PatientEngagement #GLP1

Super interesting piece on #glp1 agonists. These are some of the most revolutionary medical innovations that came to market over the last years. It is not only about the outstending #clinical impact, it is mostly about the #social, #economic, and #ethical questions that come with these products. In this piece we try and discuss some of these questions and understand the implications for #access and #use across societies. #pharmaceuticals #marketaccess #publichealth #healthsystems

GLP-1s - What are you waiting for??? The obvious is becoming more obvious by the day. Lifestyle management is an absolute necessity for all GLP-1 patients. I read these types of articles and I come away with a lot of sort ofs and maybes. Well I know this. A quality outcome driven lifestyle program doesn’t have side effects. If it’s truly outcome driven, there are no sort ofs and maybes. To all club operators, the golden ring is right in front of you. Find a partner like Nexgen360 that brings the subject knowledge we club operators lack. Not our fault. It was never needed it at this level. I didn’t learn it until I was actually working directly with physician referrals. And boy did I have a lot to learn. In this article I see a ton of opportunity. Just in the patient population dropping off before the 12 week mark alone. So I really don’t want to hear about the space between the medical world and fitness anymore. I had an opportunity just like this and I jumped in not having any idea what I was doing. And came out the other side still getting physician referrals 6 years later. Just do it. What do you have to lose. Oh yeah, memberships if you don’t. https://lnkd.in/eZzgjZ2t